The detection of BRCA1/2 mutations on tumor tissue can be challenging due to several reasons: the type of possible mutations in these genes; the fact that these mutations may be found in any part of these genes, which are very large and, as such, require the entire gene to be sequenced; and the limited quantity and low quality of DNA available from routine diagnostic FFPE tissue [8]. This evidence concerns the gene BRCA1 and neoplasm.